Difference between revisions of "Team:KU Leuven/HP/Gold Integrated"
| Line 1: | Line 1: | ||
{{KU_Leuven}} | {{KU_Leuven}} | ||
<html> | <html> | ||
| + | <script> | ||
<style type="text/css"> | <style type="text/css"> | ||
.pi_list h1 { | .pi_list h1 { | ||
| Line 45: | Line 46: | ||
<div class="item"> | <div class="item"> | ||
<p> | <p> | ||
| − | Professor Monbaliu confirmed that there is a need for a more dynamic measurement and a better evaluation of patients’ compliance which could result in less transplant rejection. He brought our attention to Tacrolimus, which is now the most used immunosuppressant. Furthermore, he mentioned the problem of patient variability and how our device should take this into account. | + | Professor Monbaliu confirmed that there is a need for a more dynamic measurement and a better evaluation of patients’ compliance which could result in less transplant rejection. He brought our attention to Tacrolimus, which is now the most used immunosuppressant. Furthermore, he mentioned the problem of patient variability and how our device should take this into account. |
<a href="#" class="read_more">Read More</a> | <a href="#" class="read_more">Read More</a> | ||
| − | + | </p> | |
<p class="more_text"> | <p class="more_text"> | ||
| − | Before our meeting with professor Monbaliu, we were doing research on the immunosuppressant cyclosporine, which we thought was used most after transplantations to reduce the chance of rejection. However, professor Monbaliu clarified that it is not cyclosporine that is mostly used nowadays, but tacrolimus is. Both drugs have the same mode of action but tacrolimus has less side effects. We were interested in using tacrolimus for our research however the drug is too expensive for us to use. Therefore, considering the information professor Monbaliu gave us and our financial possibilities, we chose to use cyclosporine. Next to this, professor Monbaliu confirmed that there is a need for a more dynamic measurement and a better evaluation of patients’ compliance which could result in less transplant rejection. Furthermore, the reduction of blood sampling is, according to the professor, a great advantage. However, a problem he brought to our attention was the fact that every patient is different which means that finding the optimal concentration of cyclosporine/tacrolimus is a challenge. Our device should thereby be calibrated individually for every patient. Bringing this information into account we considered that these differences and the problems that go with them could be assessed during clinical studies. Where different patients and their different values can be assembled, which can lead to procedures needed to determine the optimal drug concentration and calibrate our device. | + | Before our meeting with professor Monbaliu, we were doing research on the immunosuppressant cyclosporine, which we thought was used most after transplantations to reduce the chance of rejection. However, professor Monbaliu clarified that it is not cyclosporine that is mostly used nowadays, but tacrolimus is. Both drugs have the same mode of action but tacrolimus has less side effects. We were interested in using tacrolimus for our research however the drug is too expensive for us to use. Therefore, considering the information professor Monbaliu gave us and our financial possibilities, we chose to use cyclosporine. Next to this, professor Monbaliu confirmed that there is a need for a more dynamic measurement and a better evaluation of patients’ compliance which could result in less transplant rejection. Furthermore, the reduction of blood sampling is, according to the professor, a great advantage. However, a problem he brought to our attention was the fact that every patient is different which means that finding the optimal concentration of cyclosporine/tacrolimus is a challenge. Our device should thereby be calibrated individually for every patient. Bringing this information into account we considered that these differences and the problems that go with them could be assessed during clinical studies. Where different patients and their different values can be assembled, which can lead to procedures needed to determine the optimal drug concentration and calibrate our device. |
<a href="#" class="read_less">Read less</a> | <a href="#" class="read_less">Read less</a> | ||
| − | + | </p> | |
</div> | </div> | ||
</div> | </div> | ||
Revision as of 13:29, 22 August 2017
